Prognostic Effect of Immunohistochemical Scoring on Survival in Glioblastoma
Ahmet Kucukarda1, Ali Gokyer1, Vuslat Yurut Caloglu2, Hasan Murat Caloglu2, Ivo Gokmen1, Erkan Ozcan1, Muhammet Bekir Hacioglu1, Bulent Erdogan1, Sernaz Uzunoglu11Division of Medical Oncology, Department of Internal Medicine, Trakya University Faculty of Medicine, Edirne, Türkiye, 2Department of Radiation Oncology, Trakya University Faculty of Medicine, Edirne, Türkiye
Objectives: We aimed to show whether the scoring system we developed using IDH, p53 and Ki-67 markers has a prognostic feature on survival in glioblastoma. Methods: Retrospective screening was conducted on 109 patients who were followed up in our clinic. IHC scoring was performed from pathology reports. Results: Fifty-five patients (50.5%) were IDH Wild, 44 (40.4%) of them were p53 mutant, and 51 (46.8%) of them were Ki67 >30 status. Median PFS was 6.2 months (95% CI: 5.7-6.8 months), and median OS was 10.1 months (95% CI: 7.6-12.5 months). In multivariate analysis p53 status was independent prognostic factor for both PFS and OS [(HR: 2.03 (1.14- 3.61), p=0.02) and (HR: 1.86 (1.03-3.36), p=0.04), respectively]. However, Ki-67 status was an independent prognostic factor for only OS [HR: 1.94 (1.02-3.69), p=0.04]. When the patients were examined by dividing them into four IHC score groups for the combined prognostic value of IDH, p53, and Ki-67 status; differences between group 0 and the others were statistically significant. Conclusion: This study demonstrated that p53 and Ki-67 are useful, independent prognostic markers for GBM patients. Furthermore, the combined use of these three IHC markers is a statistically significant indicator for PFS and OS. Keywords: Glioblastoma, immunohistochemical scoring, IDH, p53, Ki-67
Cite This Article
Kucukarda A, Gokyer A, Caloglu V, Caloglu H, Gokmen I, Ozcan E, Hacioglu M, Erdogan B, Uzunoglu S. Prognostic Effect of Immunohistochemical Scoring on Survival in Glioblastoma. EJMI. 2023; 7(1): 42-49
Corresponding Author: Ahmet Kucukarda